Laboratory Tests in Porphyrias
0
Medically Reviewed
Pathology / Clinical Pathology

Laboratory Tests in Porphyrias

These disorders happen when certain natural chemicals build up in the body, affecting the nerves and skin. Find out how to avoid things that can make the symptoms worse.

Published:
Print this Page Email this Article
BS
Login to get unlimited free access
Be the first to comment!
Blood test Semi Flat Illustrations.
Blood test Semi Flat Illustrations. Analysis illustrations by Storyset.

Porphyrias, derived from the Greek word "porphura," meaning purple pigment, encompass a diverse array of rare disorders arising from disruptions in the heme biosynthetic pathway. This disturbance leads to the abnormal accumulation of red and purple pigments known as porphyrins within the body. Heme, an integral component of hemoglobin, undergoes synthesis through a series of distinct steps, as illustrated in Figure 1. Each step is facilitated by a specific enzyme. In instances where any of these enzymatic processes falter due to hereditary or acquired causes, precursor molecules of heme, referred to as porphyrin intermediates, amass in the blood, deposit in the skin and various organs, and are excreted in urine and feces.

The categorization of porphyrias is contingent upon the location of the defect, resulting in different types with diverse clinical manifestations, severity levels, and the specific nature of accumulated porphyrin.

Historically, porphyria has been postulated as a potential explanation for medieval tales of vampires and werewolves. This conjecture arises from notable parallels between the behaviors exhibited by individuals afflicted with porphyria and the characteristics found in folklore. These similarities include light aversion, skin mutilation upon sunlight exposure, red teeth, psychiatric disturbances, and the consumption of blood to obtain heme.

Biosynthesis of heme
Figure 1: Figure on left shows steps in the biosynthesis of heme. Some steps (first and last three) occur in mitochondria, while some occur in cytosol. Figure on right shows deficiency state associated with each enzyme. Deficiency of ALA synthase is associated with sideroblastic anemia, and deficiencies of other enzymes cause porphyria.

Detection and accurate diagnosis of porphyrias pose significant challenges, often leading to oversight or misdiagnosis. Many porphyrias lack definitive physical findings, screening tests may produce false-negative results, diagnostic criteria are ambiguously defined, and mild disorders may yield enzyme assay results within the ostensibly 'normal' range.

Heme plays a crucial role in both bone marrow, where it is essential for hemoglobin synthesis, and the liver, where it is vital for cytochromes. Consequently, porphyrias are classified into erythropoietic and hepatic types based on the site of disease expression. Hepatic porphyrias predominantly impact the nervous system, while erythropoietic porphyrias primarily affect the skin. Furthermore, porphyrias are categorized as acute and nonacute (or cutaneous) types based on their clinical presentations, as outlined in Table 1. This systematic classification enhances our understanding of porphyrias, aiding clinicians, researchers, and medical professionals in comprehending the nuances of these complex disorders.

Table 1: Various classification schemes for porphyrias
Classification based on predominant clinical manifestationsClassification based on site of expression of diseaseClassification based on mode of clinical presentation
Neuropsychiatric Hepatic Acute
Acute intermittent porphyria ALA-dehydratase porphyria ALA-dehydratase porphyria (Plumboporphyria)
ALA-dehydratase porphyria (Plumboporphyria) Acute intermittent porphyria Acute intermittent porphyria
Cutaneous (Photosensitivity) Hereditary coproporphyria Hereditary coproporphyria
Congenital erythropoietic porphyria Variegate porphyria Variegate porphyria
Porphyria cutanea tarda Erythropoietic porphyria Non-acute (cutaneous)
Erythropoietic protoporphyria Congenital erythropoietic porphyria Porphyria cutanea tarda
Mixed (Neuropsychiatric and cutaneous) Erythropoietic protoporphyria Congenital erythropoietic porphyria
Hereditary coproporphyria Hepatic/Erythropoietic Erythropoietic protoporphyria
Variegate porphyria Porphyria cutanea tarda -

The inheritance patterns associated with porphyrias manifest as either autosomal dominant or recessive. The majority of acute porphyrias follow an autosomal dominant inheritance, signifying the transmission of a single abnormal gene copy. Consequently, the activity of the deficient enzyme is halved, resting at 50%. In instances where the hepatic heme level diminishes due to various factors, the activity of ALA synthase is spurred, resulting in an escalation of heme precursors up to the point of the enzyme defect. This surge in heme precursors precipitates the onset of symptoms characteristic of acute porphyria. Notably, as the heme level normalizes, the associated symptoms subside.

The accumulation of porphyrin precursors presents a noteworthy occurrence in lead poisoning, attributed to the inhibition of the enzyme aminolevulinic acid dehydratase within the heme biosynthetic pathway. This phenomenon can simulate the clinical presentation of acute intermittent porphyria.

Understanding the genetic underpinnings and enzymatic intricacies of porphyrias is crucial for clinicians, researchers, and medical professionals. The autosomal dominant inheritance pattern underscores the significance of a singular abnormal gene copy in the manifestation of acute porphyrias. Additionally, the intricate interplay between heme levels and enzymatic activity elucidates the nuanced triggers and resolution of acute porphyria symptoms. Moreover, the correlation between lead poisoning and the disruption of the heme biosynthetic pathway highlights the diagnostic challenges posed by conditions that mimic porphyric presentations, necessitating a keen clinical acumen for accurate differentiation.

Clinical Features

The clinical manifestations of porphyrias exhibit variability contingent upon the specific type of the disorder. Acute porphyrias, for instance, manifest with a spectrum of symptoms, including acute and intense abdominal pain, vomiting, constipation, chest pain, emotional and mental disturbances, seizures, hypertension, tachycardia, sensory deficits, and muscular weakness. This diverse array of clinical presentations underscores the complexity of acute porphyrias and the multisystemic impact they can exert.

In contrast, cutaneous porphyrias present a distinctive set of clinical features. Patients with cutaneous porphyrias commonly experience photosensitivity, characterized by the development of redness and blistering of the skin upon exposure to sunlight. Additional symptoms include itching, necrosis of the skin and gums, and an observable increase in hair growth over the temples. This distinctive clinical profile, outlined in Table 2, provides a comprehensive overview of the characteristic features associated with cutaneous porphyrias.

Understanding the nuanced clinical features associated with different types of porphyrias is pivotal for accurate diagnosis and effective management. The delineation of symptoms, ranging from abdominal pain and neurological manifestations in acute porphyrias to the distinctive photosensitivity and dermatological changes in cutaneous porphyrias, enhances the knowledge base for clinicians, researchers, and medical professionals. Such precision in characterizing the clinical landscape facilitates targeted interventions and improves patient outcomes.

Table 2: Clinical characteristics of porphyrias
PorphyriaDeficient enzymeClinical featuresInheritanceInitial test
Acute intermittent porphyria (AIP)* PBG deaminase Acute neurovisceral attacks; triggering factors+ (e.g. drugs, diet restriction) Autosomal dominant Urinary PBG; urine becomes brown, red, or black on standing
Variegate porphyria Protoporphyrinogen oxidase Acute neurovisceral attacks + skin fragility, bullae Autosomal dominant Urinary PBG
Hereditary coproporphyria Coproporphyrinogen oxidase Acute neurovisceral attacks + skin fragility, bullae Autosomal dominant Urinary PBG
Congenital erythropoietic porphyria Uroporphyrinogen cosynthase Onset in infancy; skin fragility, bullae; extreme photosensitivity with mutilation; red teeth and urine (pink red urinestaining of diapers) Autosomal recessive Urinary/fecal total porphyrins; ultraviolet fluorescence of urine, feces, and bones
Porphyria cutanea tarda* Uroporphyrinogen decarboxylase Skin fragility, bullae Autosomal dominant (some cases) Urinary/fecal total porphyrins
Erythropoietic protoporphyria* Ferrochelatase Acute photosensitivity Autosomal dominant Free erythrocyte protoporphyrin
Disorders marked with * are the three most common porphyrias. PBG: Porphobilinogen

The manifestation of symptoms in porphyrias is intricately linked to various triggers, encompassing pharmaceutical agents and lifestyle factors. Certain drugs, such as barbiturates, oral contraceptives, diazepam, phenytoin, carbamazepine, methyldopa, sulfonamides, chloramphenicol, and antihistamines, can serve as catalysts for symptoms. Emotional or physical stress, infections, dietary changes, fasting, substance abuse, premenstrual periods, smoking, and alcohol consumption also constitute potential triggers, amplifying the complexity of porphyria management.

Autosomal dominant porphyrias comprise a diverse group of disorders, including acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda, erythropoietic protoporphyria (predominantly), and hereditary coproporphyria. In contrast, autosomal recessive porphyrias encompass congenital erythropoietic porphyria, erythropoietic protoporphyria (in a limited number of cases), and ALAdehydratase porphyria, also known as plumboporphyria.

Understanding the array of triggers and the genetic underpinnings of different porphyria types is pivotal for comprehensive patient care. The intricate interplay between pharmaceutical agents, lifestyle factors, and the distinct genetic characteristics of autosomal dominant and recessive porphyrias underscores the necessity for a nuanced approach in diagnosis and management. This multifaceted perspective equips medical professionals, and researchers with the knowledge required to navigate the complexities of porphyria, facilitating enhanced patient outcomes and advancing scientific understanding in the field.

Laboratory Diagnosis

The diagnosis of porphyria involves conducting tests on blood, urine, and feces, particularly during symptomatic periods. Achieving a timely and precise diagnosis is crucial for the effective management of porphyrias. Given the diverse and extensive clinical features associated with porphyrias, they are often considered in the differential diagnosis of various medical conditions. Most routine hospital laboratories are equipped to perform initial investigations when porphyria is suspected. However, for the identification of specific porphyria types, specialized laboratories with advanced testing capabilities become essential.

In the diagnostic process, blood, urine, and fecal analyses play a pivotal role, allowing for the detection of characteristic abnormalities during symptomatic phases. This comprehensive approach ensures a more accurate identification of porphyria subtypes, facilitating targeted and tailored therapeutic strategies.

Considering the intricate nature of porphyria diagnoses, collaboration with specialized laboratories becomes imperative. These facilities possess the advanced technologies and expertise required for in-depth analyses, enabling the discrimination between various porphyria types. This collaboration enhances the precision of the diagnostic process, contributing to improved patient outcomes and informed decision-making in the realm of porphyria management.

In essence, the diagnostic journey for porphyria demands a synergistic effort between routine hospital laboratories and specialized facilities, with a focus on leveraging advanced testing methodologies to unravel the complexities inherent in these conditions. This collaborative approach underscores the significance of accurate diagnostics in paving the way for effective porphyria management strategies.

Initial Studies

In the assessment of suspected acute porphyrias, specifically during acute neurovisceral attacks, it is imperative to submit a freshly collected, randomly obtained urine sample (10-20 ml) for the detection of heightened urinary excretion of porphobilinogen (PBG) (refer to Figure 2). Notably, in acute intermittent porphyria (AIP), the urine may exhibit a reddish or brown hue upon standing, as illustrated in Figure 3.

For cases where cutaneous porphyrias are suspected, with manifestations such as acute photosensitivity lacking skin fragility, a comprehensive diagnostic approach is warranted. This includes analyzing free erythrocyte protoporphyrin (FEP) in EDTA blood for the diagnosis of erythrocytic protoporphyria. Additionally, for all other cutaneous porphyrias characterized by skin fragility and bullae, an examination of fresh, random urine (10-20 ml) and either feces (5-10 g) or plasma is indispensable for identifying excess porphyrins. Detailed guidance on this diagnostic protocol is provided in Figure 4 and Table 2.

In essence, the diagnostic strategy for suspected porphyrias involves specific tests tailored to the clinical presentation. The utilization of various specimen types, including urine, blood, feces, and plasma, is crucial for the accurate identification of porphyrin abnormalities. The distinct visual cues, such as the color changes in urine associated with AIP, serve as valuable indicators in the diagnostic process. This meticulous and multifaceted approach ensures a comprehensive evaluation, facilitating precise diagnoses in the intricate landscape of porphyrias.

Evaluation of acute neurovisceral porphyria
Figure 2: Evaluation of acute neurovisceral porphyria
Red coloration of urine on standing in acute intermittent porphyria
Figure 3: Red coloration of urine on standing in acute intermittent porphyria
Evaluation of cutaneous porphyrias
Figure 4: Evaluation of cutaneous porphyrias

In addition to aiding in the diagnosis, the identification of specific heme intermediates excreted in urine or feces plays a pivotal role in pinpointing the site of defect in porphyria. Heme precursors, extending up to coproporphyrinogen III, exhibit water solubility, enabling their detection in urine. Conversely, protoporphyrinogen and protoporphyrin, being insoluble in water, are excreted through bile and can be identified in fecal samples. It is essential to shield all samples from light to preserve their integrity.

The requisite samples for a comprehensive porphyria assessment include a 10-20 ml fresh, random urine sample devoid of any preservatives, 5-10 g of wet fecal weight, and blood anticoagulated with EDTA. Each specimen type offers distinct insights into the porphyrin profile, contributing to a thorough evaluation of the disorder. The meticulous collection and analysis of these samples serve as critical steps in unraveling the intricacies of porphyria, ensuring a comprehensive understanding of the disorder's manifestations and facilitating targeted interventions.

In essence, the choice of sample type is guided by the solubility characteristics of specific heme intermediates, aligning with their excretion pathways. This systematic approach, coupled with stringent measures to protect samples from light-induced alterations, underscores the importance of precision and accuracy in the diagnostic process.

Test for Porphobilinogen in Urine

The Ehrlich’s aldehyde test serves as a diagnostic tool for detecting porphobilinogen (PBG) in urine. In this assay, Ehrlich’s reagent, composed of p-dimethylaminobenzaldehyde, reacts with PBG, resulting in the formation of a distinctive red color. The characteristic red product exhibits an absorption spectrum with a peak at 553 nm and a shoulder at 540 nm. It's noteworthy that both urobilinogen and porphobilinogen elicit a similar reaction, necessitating additional tests to discern between the two substances. To distinguish PBG from urobilinogen, solvent extraction can be employed, as outlined in the Watson-Schwartz test. This additional step is crucial for achieving specificity in the diagnostic process.

It is essential to recognize that levels of PBG might appear normal or near normal between attacks. Consequently, to mitigate the risk of false-negative results, it is imperative to conduct the test during an acute attack. This strategic timing ensures a more accurate and reliable assessment of PBG levels, contributing to a precise diagnosis and informed clinical decision-making.

Test for Total Porphyrins in Urine

The quantification of total porphyrins within an acidified urine sample is achievable through spectrophotometry, leveraging the distinct absorbance peak of porphyrins around 400 nm. This method allows for a semiquantitative estimation of porphyrin levels, providing valuable insights into the porphyrin profile present in the urine sample. Spectrophotometry, with its ability to measure the absorption of light at specific wavelengths, offers a precise and objective means of assessing the concentration of porphyrins in the given sample.

In this analytical approach, the intense absorbance peak observed around 400 nm serves as a reliable marker for the presence of porphyrins. This peak reflects the characteristic absorption spectrum of porphyrins, allowing for their identification and quantification in a systematic and accurate manner. The semiquantitative nature of the estimation enhances the diagnostic utility of the method, providing clinicians and researchers with valuable information regarding the porphyrin content in the urine.

The utilization of spectrophotometry in conjunction with acidified urine samples offers a robust technique for detecting and estimating total porphyrins. This method, marked by its precision and objectivity, contributes to the comprehensive assessment of porphyrin levels, facilitating diagnostic and research endeavors within the realm of porphyria evaluation.

Test for Total Porphyrins in Feces

The quantification of total porphyrins in fecal samples involves the use of spectrophotometry on an acidic extract of the specimen. However, a crucial preparatory step is required to eliminate interference from dietary chlorophyll, which also absorbs light around 400 nm. This interference is addressed through diethyl ether extraction, ensuring a more accurate and specific assessment of total porphyrin levels.

In the analytical process, an acidic extract of the fecal sample serves as the basis for spectrophotometric analysis. Spectrophotometry, with its ability to measure the absorption of light at specific wavelengths, allows for the precise determination of total porphyrins. The focus on an acidic environment facilitates optimal conditions for the assessment of porphyrin content.

To enhance the specificity of the analysis, the extraction of dietary chlorophyll using diethyl ether becomes imperative. This preparatory step is essential as chlorophyll absorbs light in a similar range as porphyrins, potentially leading to inaccurate measurements. By effectively removing this interference, the spectrophotometric analysis can provide more reliable and meaningful data regarding the concentration of total porphyrins in the fecal sample.

The process of determining total porphyrins in feces through spectrophotometry necessitates a meticulous approach, including the removal of dietary chlorophyll through diethyl ether extraction. This method ensures the accuracy and specificity of the analysis, contributing to the reliability of results in the evaluation of porphyrin levels in fecal samples.

Evaluation of Porphyrins in Erythrocytes and Plasma: Modern Techniques

Contemporary methodologies have supplanted traditional approaches such as visual examination for porphyrin fluorescence, as well as solvent fractionation and spectrophotometry. The advent of fluorometric methods represents a significant advancement in the analysis of porphyrins in erythrocytes and plasma.

Fluorometric techniques have emerged as the preferred means of assessing porphyrins, offering heightened precision and sensitivity compared to their predecessors. These methods leverage the unique fluorescence properties of porphyrins, providing a more refined and objective approach to their detection and quantification.

By utilizing fluorometry, researchers and medical professionals can achieve a clearer understanding of porphyrin levels in erythrocytes and plasma. This modernized approach enhances both the accuracy and efficiency of porphyrin testing, aligning with the evolving standards of scientific analysis in hematology and related fields.

This transition to fluorometric methods underscores the commitment to staying at the forefront of scientific advancements, ensuring that diagnostic and research practices remain not only rigorous but also in harmony with the latest technological innovations.

Comprehensive Assessment for Porphyria Diagnosis

Upon obtaining a positive result in the initial porphyria screening, a more in-depth analysis becomes imperative. This involves the quantification of porphyrin concentrations in urine, feces, and blood, a crucial step in establishing a precise and specific diagnosis. The tables below (Tables 3 and 4) provide detailed insights into the diagnostic criteria and reference values for this comprehensive evaluation.

By meticulously measuring porphyrin levels in these biological samples, healthcare professionals can discern the specific type and severity of porphyria, facilitating targeted and effective management strategies. This comprehensive approach not only confirms the presence of porphyria but also aids in tailoring treatment plans to the individual nuances of the patient's condition.

As with any diagnostic process, the accuracy and reliability of results depend on the proficiency of the laboratory techniques employed and the adherence to standardized protocols. This commitment to precision ensures that the gathered data is not only scientifically robust but also forms the cornerstone for informed clinical decisions and patient care.

Table 3: Diagnostic patterns of concentrations of heme precursors in acute porphyrias
PorphyriaUrineFeces
Acute intermittent porphyria PBG, Copro III
Variegate porphyria PBG, Copro III Proto IX
Hereditary coproporphyria PBG, Copro III Copro III
PBG: Porphobilinogen; Copro III: Coproporphyrinogen III; Proto IX: Protoporphyrin IX.
Table 4: Diagnostic patterns of concentrations of heme precursors in cutaneous porphyrias
PorphyriaUrineFecesErythrocytes
Congenital erythropoietic porphyria Uro I, Copro I Copro I
Porphyria cutanea tarda Uroporphyrin Isocopro
Erythropoietic protoporphyria Protoporphyrin
Uro I: Uroporphyrinogen I; Copro I: Coproporphyrinogen I; Isocopro: Isocoproporphyrinogen.

Diagnostic Challenges in Latent Porphyrias and Remission Periods

During latent porphyrias and periods of remission, individuals may exhibit normal porphyrin levels, posing a diagnostic challenge. In such instances, a comprehensive approach involving enzymatic and DNA testing becomes imperative for an accurate diagnosis. These advanced testing methods delve into the genetic and enzymatic aspects, providing a more nuanced understanding of porphyria manifestation even in the absence of elevated porphyrin levels.

Upon confirming a diagnosis of porphyria, a critical next step involves the systematic examination of close family members for the presence of the disorder. This proactive approach is essential for early detection and intervention. Family members testing positive for porphyria should undergo counseling, equipping them with valuable insights into potential triggering factors and empowering them to make informed lifestyle choices that mitigate the risk of symptomatic episodes.

This meticulous diagnostic and familial investigation strategy not only aids in individual patient management but also contributes to the broader goal of familial health and well-being. By addressing latent cases and involving family members, healthcare professionals can establish a more comprehensive and effective framework for the understanding and management of porphyrias.

Last Updated:

Cite this page:

Dayyal Dg.. “Laboratory Tests in Porphyrias.” BioScience. BioScience ISSN 2521-5760, 03 August 2017. <https://www.bioscience.com.pk/en/topics/pathology/laboratory-tests-in-porphyrias>. Dayyal Dg.. (2017, August 03). “Laboratory Tests in Porphyrias.” BioScience. ISSN 2521-5760. Retrieved December 06, 2023 from https://www.bioscience.com.pk/en/topics/pathology/laboratory-tests-in-porphyrias Dayyal Dg.. “Laboratory Tests in Porphyrias.” BioScience. ISSN 2521-5760. https://www.bioscience.com.pk/en/topics/pathology/laboratory-tests-in-porphyrias (accessed December 06, 2023).
  • Comment
  • Posted by Dayyal Dg.
Start a Conversation
Add comment

Follow us on social media

End of the article